| Literature DB >> 32452052 |
Shirin Tavakoli1,2, Hamid Reza Ghaderi Jafarbeigloo3, Ali Shariati2, Afsaneh Jahangiryan4, Faezeh Jadidi5, Mohammd Amin Jadidi Kouhbanani6, Ali Hassanzadeh2, Majid Zamani7, Kamran Javidi8, Adel Naimi9.
Abstract
In recent decades, mesenchymal stromal cells (MSCs) biomedical utilizing has attracted worldwide growing attention. After the first report of the human MSCs obtaining from the bone marrow (BM) tissue, these cells were isolated from wide types of the other tissues, ranging from adipose tissue to dental pulp. Their specific characteristics, comprising self-renewality, multipotency, and availability accompanied by their immunomodulatory properties and little ethical concern denote their importance in the context of regenerative medicine. Considering preclinical studies, MSCs can modify immune reactions during tissue repair and restoration, providing suitable milieu for tissue recovery; on the other hand, they can be differentiated into comprehensive types of the body cells, such as osteoblast, chondrocyte, hepatocyte, cardiomyocyte, fibroblast, and neural cells. Though a large number of studies have investigated MSCs capacities in regenerative medicine in varied animal models, the oncogenic capability of unregulated MSCs differentiation must be more assessed to enable their application in the clinic. In the current review, we provide a brief overview of MSCs sources, isolation, and expansion as well as immunomodulatory activities. More important, we try to collect and discuss recent preclinical and clinical research and evaluate current challenges in the context of the MSC-based cell therapy for regenerative medicine.Entities:
Keywords: cell therapy; differentiation; mesenchymal stromal cells (MSCs); regenerative medicine; sources
Mesh:
Year: 2020 PMID: 32452052 DOI: 10.1002/jcp.29803
Source DB: PubMed Journal: J Cell Physiol ISSN: 0021-9541 Impact factor: 6.384